Topoisomerase II (Topo II) is required to separate intertwined sister chromatids before chromosome segregation can occur in mitosis 1 . However, it remains to be resolved whether Topo II has any role in checkpoint control. Here we report that when phosphorylated, Ser 1524 of Topo IIα acts as a binding site for the BRCT domain of MDC1 (mediator of DNA damage checkpoint protein-1), thereby recruiting MDC1 to chromatin. Although Topo IIα-MDC1 interaction is not required for checkpoint activation induced by DNA damage, it is required for activation of the decatenation checkpoint. Mutation of Ser 1524 results in a defective decatenation checkpoint. These results reveal an important role of Topo II in checkpoint activation and in the maintenance of genomic stability.
. The checkpoint is activated when cells are treated with catalytic Topo II inhibitors, such as bis (2, 6-dioxopiperazine) derivatives 4) . These inhibit the ATPase activity of Topo II and stabilize the enzyme in a closed-clamp form, rather than stabilizing the Topo II DNA-cleavable complex, which is the mechanism of action of Topo II inhibitor etoposide 5 . Therefore, in contrast to etoposide 5, 6 , ICRF-193 and ICRF-187 do not induce extensive DNA breaks. Indeed, many studies suggest that the decatenation checkpoint is distinct from the DNA damage checkpoint. For example, stem cells, progenitor cells and certain lung and bladder cancer cells have an intact DNA damage checkpoint, whereas they lack a decatenation checkpoint [7] [8] [9] . Furthermore, ICRF-193 induces G2-phase arrest that is independent of the DNA checkpoint kinases ATM, Chk1 and Chk2 (ref. 3). Despite these differences, these two checkpoints do require some common checkpoint proteins, notably, ATR, BRCA1 and WRN 3, 7, 10 . Here we report an unexpected role for Topo IIα in the activation of the decatenation checkpoint.
MDC1 is an important multi-functional checkpoint protein 11 . To identify proteins associated with its BRCT domain we performed affinity purification using glutathione S-transferase (GST)-BRCT. As BRCT domains bind phospho-Ser or phosphor-Thr motifs 12, 13 , we also treated HeLa cell lysates with λ-phosphatase. In pulldown assays, three bands showed specific binding to the MDC1 BRCT domain (Fig. 1a) . These interactions were abolished by λ-phosphatase treatment. We excised these bands and sequencing by mass spectrometry revealed that they were Topo IIα, DNA ligase III and XRCC1. Western blotting using antiTopo IIα antibodies confirmed that the BRCT domain of MDC1 binds Topo IIα in a phosphorylation-dependent manner (Fig. 1b) . We further verified the interaction between MDC1 and Topo IIα in vivo, by coimmunoprecipitation ( Fig. 1c, d ). Similarly, we observed the interaction between MDC1 and DNA ligase III-XRCC1 in vivo (data not shown).
As Topo IIα was isolated by the BRCT domain of MDC1 in vitro, we generated MDC1 with the BRCT domain deleted, and examined its interaction with Topo IIα in vivo. Deletion of the BRCT domain markedly decreased the MDC1-Topo IIα interaction (Fig. 1e) , confirming that the MDC1 BRCT domain is required for the MDC1-Topo IIα interaction in vivo.
To map the region of Topo IIα that binds MDC1, we generated a series of Topo IIα deletion mutations. We found that deletion of the 71 residues in the carboxy-terminal region significantly reduced the MDC1-Topo IIα interaction (Fig. 2a) . The MDC1 BRCT domain is predicted to preferentially bind a phospho-pSer(Thr)xxPhe motif 14 . Within the 71 amino acids of the Topo IIα C-terminal region (residues 1461-1531), Ser 1496 is followed by Phe at the +3 position, but Ser 1496 is not known to be phosphorylated in vivo. On the other hand, Ser 1524, which is known to be phosphorylated in vivo 15 , has Asp not Phe at the +3 position. We mutated these two sites individually and tested whether they are required for MDC1 binding. In vitro pulldown assays (Fig. 2b ) and co-immunoprecipitation (Fig. 2c) showed that mutation of Ser 1496 did not affect the interaction between the MDC1 BRCT domain and Topo IIα (data not shown), whereas mutation of the Ser 1524 site abolished this interaction. These results indicate that Ser 1524 is required for MDC1 binding.
To verify these results, we performed in vitro pulldown assays using peptides containing non-phosphorylated Ser 1524 or phosphorylated Ser 1524 (pSer 1524). Peptides containing pSer 1524 preferentially bound the MDC1 BRCT domain (Fig. 2d) , confirming that the MDC1-Topo IIα interaction is mediated by the BRCT domain of MDC1 and by phosphorylation at the Ser 1524 site of Topo IIα.
l e t t e r s
Although phospho-peptide mapping and sequencing 15 has shown that phosphorylation at Ser 1524 of Topo IIα occurs in vivo, no antibody is available to specifically detect this event. To verify that the Ser 1524 site of Topo IIα is phosphorylated in vivo, we generated anti-pSer 1524 antibodies and confirmed their specificity ( Supplementary Information,  Fig. S1a-c) . Using these antibodies, we found that phosphorylation of Ser 1524 occurs preferentially when cells are at the G2-M transition (Fig. 2e) , suggesting a potential functional role of pSer 1524 at this stage of the of cell cycle.
Although phosphorylation of Topo IIα at Ser 1524 was identified more than 10 years ago, the functional significance of this event is unclear. It has been suggested that casein kinase II (CK2) phosphorylates Ser 1524 (ref. 15) . However, when cells were treated with either of the CK2 inhibitors 5,6-dichlorobenzimidazole riboside (DRB) or 4,5,6,7-tetrabromobenzotriazole (TBB), we did not observe any decrease in pSer 1524 (data not shown), suggesting that kinases other than CK2 may be responsible for Topo IIα Ser 1524 phosphorylation in vivo. There are also conflicting results regarding the relationship between Topo IIα activity and its phosphorylation. Although some reports suggest that CK2-mediated phosphorylation of Topo IIα enhances its decatenation activity 16 , other reports show no such effect 17, 18 . To further investigate this phosphorylation event we expressed FLAG-tagged wild-type Topo IIα (Topo IIα WT ) or mutant Topo IIα (Topo IIα S1524A ), in 293T cells, and purified the recombinant Topo IIα by affinity purification. Decatenation assays were performed using purified Topo IIα WT and Topo IIα S1524A , with kinetoplast DNA as the substrate. We did not observe any marked difference in activity between Topo IIα WT and Topo IIα S1524A (Fig. 3a) , which suggests that Topo IIα phosphorylation at Ser 1524 does not have a major regulatory role in Topo IIα decatenation activity.
Thus, the functional significance of Topo IIα Ser 1524 phosphorylation and its interaction with MDC1 in vivo remains unclear. As MDC1 is known to be important for checkpoint regulation, we speculated that MDC1 may also have a role in the decatenation checkpoint. Indeed, downregulation of MDC1 in HT1080 (human fibrosarcoma) cells resulted in defective decatenation and DNA damage checkpoints: cells depleted of MDC1 failed to block mitotic entry after ICRF-193, ionizing radiation (IR), mitomycin C (MMC) or UV treatment ( Fig. 3b, c ; Supplementary Information, Fig. S1d, e) . These results implicate MDC1 in the regulation of the decatenation checkpoint, in addition to its role in checkpoint activation induced by DNA damage.
As MDC1 interacts with Topo IIα, we further proposed that the MDC1-Topo IIα interaction, and phosphorylation of Topo IIα Ser 1524, may be involved in the decatenation checkpoint. We generated HT1080 cells stably expressing short interfering RNA (siRNA)-resistant Topo IIα WT or Topo IIα S1524A , both of which contain silent mutations in the region targeted by Topo IIα siRNA. These cells were transfected with Topo IIα siRNA to deplete endogenous Topo IIα. When siRNAtransfected cells were treated with ICRF-193, those expressing Topo IIα WT had an intact decatenation checkpoint ( Fig. 3d ; Supplementary  Information, Fig. S1e) . Interestingly, cells expressing Topo IIα S1524A had a defective decatenation checkpoint ( Fig. 3d; Supplementary Information,  Fig. S1e ), indicating that Ser 1524 of Topo IIα is required for the decatenation checkpoint. On the other hand, UV-, MMC-or IR-treated Topo IIα S1524A cells showed an intact G2 arrest induced by DNA damage ( Fig. 3e; Supplementary Information, Fig. S1d, e) . These results suggest that Topo IIα Ser 1524 phosphorylation specifically regulates the , could also be due to enhanced mitotic arrest rather than defective G2 arrest. To distinguish between these possibilities, we treated these cells with both ICRF-193 and nocodazole, and examined the mitotic population at several time-points. Control cells remained blocked at mitotic entry, whereas cells with MDC1 downregulation or expressing Topo IIα S1524A continued to accumulate in mitosis (Fig. 3f) , suggesting a failure to arrest at G2 in these cells. Finally, to confirm that the ICRF-193-induced checkpoint is due to its action on Topo IIα, we used Topo IIα
R162Q
, a mutant shown to be resistant to ICRF-type agents 19 . We found that ICRF-193 failed to induce G2 arrest in cells expressing Topo IIα R162Q ( Fig. 3g) , suggesting that ICRF-193 acts through Topo II to induce the decatenation checkpoint.
In contrast to previous studies suggesting that ICRF-type Topo II inhibitors induce DNA damage 20,21 , we did not observe induction of foci or changes in levels of the well-recognized DNA damage marker, γH2AX, under our treatment conditions (ICRF, 2 µM for 1 h; ( Supplementary Information, Fig. S2a , e). We were also unable to detect induction of NBS1 or BRCA1 foci formation or the stabilization of p53 ( Supplementary Information, Fig. S2a, b) . Interestingly, we observed a slight increase in ATM phosphorylation after ICFR-193 treatment ( Supplementary Information, Fig. S2c ), even though no induction of phospho-ATM foci was found ( Supplementary Information, Fig. S2a ). This is consistent with a previous report 7 suggesting that ICRF-193 could induce a conformational change in chromosomes in the absence of DNA damage 22 . However, ATM is not required for the decatenation checkpoint activation ( Supplementary Information, Fig. S2f, g ). We did not detect Chk1 phosphorylation ( Supplementary Information, Fig. S2d ). There was no detectable DNA damage and results suggest that the classical DNA damage checkpoint was not induced under the conditions used for the decantenation assay. However, conditions used in previous studies to detect DNA damage 20, 21 , involving prolonged treatment with ICRF-193 (>3 h), did result in the induction of γH2AX, phospho-ATM, BRCA1 and NBS1 foci ( Supplementary Information, Fig. S2a ). It is likely that some cells escaped G2 arrest, entering mitosis in the presence of catenated chromosomes, causing DNA damage.
Defects in the decatenation checkpoint lead to genomic instability because cells enter mitosis in the presence of chromatid entanglement (pseudomitosis) 9 . Indeed, we found that ICRF-193 treatment resulted in an increased incidence of pseudomitosis in cells expressing Topo IIα S1524A , compared with Topo IIα WT cells (Fig. 3h) . Additionally, cells Supplementary Information, Fig. S3 . expressing Topo IIα S1524A showed an increased incidence of spontaneous pseudomitosis in the absence of ICRF-193 (Fig. 3i) . These results provide evidence that the MDC1-Topo IIα interaction is important in maintaining genomic stability following chromosome entanglement.
Although the MDC1-Topo IIα interaction is important for activation of the decatenation checkpoint, it is not clear how cells sense chromosome catenation and activate the checkpoint. Interestingly, we found that ICRF-193 treatment induced a significant increase in the MDC1-Topo IIα interaction in both HT1080 cells and mouse embryonic fibroblasts ( Fig. 4a; Supplementary Information, Fig. S2h ). However, although the MDC1-Topo IIα interaction requires Ser 1524 phosphorylation, we did not observe an increase in Ser 1524 phosphorylation after Topo IIα inhibition (Fig. 4b) . This raises the question of how ICRF-193 treatment increases MDC1-Topo IIα interaction. It has been shown previously that methylation at histone H3 and H4 can recruit DNA damage factors 53BP1 to sites of DNA damage 23, 24 , whereas the overall methylation level of histone H3 and H4 does not change. A possible interpretation is that DNA breaks induce conformational changes, exposing previously buried methylation sites. We speculate that inhibition of Topo IIα by ICRF-193 can also induce conformational changes 25 and expose pSer 1524 sites that were previously buried, without affecting overall Ser 1524 phosphorylation. The exposed pSer 1524 would then recruit MDC1 to chromatin and activate the decatenation checkpoint. To test this possibility, we performed nuclear fractionation experiments. We found that ICRF-193 treatment increased chromatin-associated MDC1 (Fig. 4c) but the amount of Ser 1524-phosphorylated Topo IIα or total Topo IIα remained unchanged. This increase in chromatin-bound MDC1 was abolished in the Topo IIα S1524A mutants (Fig. 4d) . These results support our hypothesis that after Topo IIα inhibition, Topo IIα pSer 1524 sites are exposed, recruiting MDC1 to chromatin and thus activating the decatenation checkpoint.
ATR-dependent inhibition of the mitosis regulator polo-like kinase 1(PLK1) has been proposed to be one mechanism for G2 arrest after Topo IIα inhibition 26 . To further explore how the MDC1-Topo IIα interaction may regulate the decatenation checkpoint, we assessed PLK1 kinase activity in MDC1-expressing or MDC1-deficient cells treated with ICRF-193. PLK1 activity was inhibited in cells expressing MDC1 but not in MDC1-deficient cells ( Supplementary Information, Fig. S2i ). To test whether disruption of the MDC1-Topo IIα interaction specifically affects PLK1 inhibition, we used HT1080 cells stably expressing Topo IIα WT or Topo IIα S1524A
. These cells were transfected with Topo IIα siRNA, and then treated with ICRF-193. PLK1 activity was then evaluated using casein as the substrate. PLK1 activity was inhibited in cells expressing Topo IIα WT but not in Topo IIα S1524A (Fig. 4e) . These results indicate that the MDC1-Topo IIα interaction regulates the blockade of PLK1 activity in response to Topo IIα inhibition.
Although PLK1 activity is not essential for mitotic entry, inhibition or downregulation of PLK1 delays mitotic entry 27 . We also found that inhibition of PLK1 using the specific inhibitor ON01910 blocked mitotic entry in the initial hours of treatment ( Supplementary Information,  Fig. S2j ). To further confirm that PLK1 inhibition is required for ICRF-193-induced G2 arrest, we expressed wild-type PLK1 (PLK1 (Fig. 4f) . These results are consistent with a previous study 26 and suggest that inhibition of PLK1 is important for activation of the decatenation checkpoint.
In conclusion, our data suggest that Topo IIα directly controls the decatenation checkpoint. Although it has been speculated that Topo IIα has a role in checkpoint signalling 28, 29 , experimental evidence supporting this hypothesis has been lacking as it is difficult to separate this role from its role in DNA decatenation. However, we were, able to achieve this by using the Topo IIα S1524A mutant. Our results indicate that the S1524A mutation affects only ICRF-193-induced checkpoint activation, but not IR-, UV-or MMC-induced checkpoint activation, suggesting that the checkpoint regulated by Topo IIα Ser 1524 phosphorylation is different from the classical DNA damage checkpoint. We hypothesize that the Topo IIα pSer 1524 site becomes exposed after ICRF-193 treatment, and can then bind and recruit MDC1 to chromatin, thereby activating the decatenation checkpoint in response to chromosome entanglement (Fig. 4g) . These results reveal a mechanism by which cells maintain genomic stability.
MeTHoDS
Protein purification. GST or GST-MDC1 BRCT domain was conjugated to glutathione-Sepharose beads and then incubated with nuclear extracts (untreated or treated with λ-phosphatase) prepared from 5 l of HeLa cells (obtained from NCCC ) at 4 °C for 2 h. The Sepharose beads were then washed extensively and proteins retained on the beads were eluted with reduced glutathione (2 mM), separated by SDS-PAGE, and stained with Coomassie blue. Bands specifically identified in GST-MDC1 BRCT pulldown samples were excised and analysed using mass spectrometry.
Immunoprecipitation and western blotting. Cells were lysed with modified NETN lysis buffer (0.5% NP40, 250 mM NaCl, 50 mM Tris, 1 mM EDTA). Cell lysates were then centrifuged and supernatants were subjected to either immunoprecipitation or pulldown with the indicated antibodies or GST-MDC1 BRCT domain. Anti-FLAG and anti-β-actin antibodies were from Sigma. Anti-PLK1 antibodies (monoclonal) were from Zymed (Invitrogen). Anti-MDC1 antibodies were generated in rabbit using GST-1-250 of MDC1 (CoCalico). Anti-Topo IIα antibodies were generated in rabbit using the peptide IKYLEESDEDDLF, or purchased from NeoMakers. Anti-phospho-Ser 1524 Topo IIα antibodies were generated in rabbit using phosphorylated peptide IKYLEEpSDEDDLF. Prebleeds from rabbits were used as controls in immunoprecipitation experiments. For western blotting, antibodies were used a concentration of at 0.5 µg ml -1 . siRNA transfection. All siRNAs were synthesized by Dharmacon. The sequence for Topo IIα siRNA corresponded to Topo IIα cDNA 78-97 (with the sense strand sequence 5´-AAGACTGTCTGTTGAAAGAA-3´). The sequence for MDC1 siRNA and the siRNA.transfection method were as described previously 30 .
Decatenation checkpoint assay. Cells were treated with ICRF-193 (2 µM) for 1 h, fixed and stained with anti-phospho-H3 antibodies or anti-cyclinB1 antibodies (Santa Cruz Biotechnology). Mitotic populations were then determined by FACS and microscopic analysis.
Nuclear fractionation. Cells were treated with dimethylsulphoxide (DMSO) or ICRF-193 (2 μM) for 1 h, then collected. After washing with PBS, cells were resuspended in 80 μl high salt buffer with NP40 (50 mM Hepes, 150 mM NaCl, 1 mM EDTA, 0.05% NP40, 25 mM NaF, 10 mM β-glycerolphosphate, 5 μg ml -1 aprotinin, 5 μg ml -1 pepstatin, 5 μg ml -1 leupeptin, 1 mM Na 3 VO 4 ), and incubated for 5 min on ice. Cell lysates were spun at 3,000g. for 5 min at 4 °C, the supernatants were collected as fraction I. Pellets were washed once with 80 μl high-salt buffer with NP40 and the supernatants were collected as fraction II. Pellets were then resuspended in 80 μl RIPA buffer (with protease inhibitor) and incubated for 20 min on ice. After centrifugation, the supernatants were collected as fraction III. The pellets as the chromatin fractions were then resuspended in SDS sample buffer. Each fraction (20 μl) was loaded and separated by SDS-PAGE. PLK1 kinase assay. Cells were treated with DMSO or ICRF-193 (2 μM) for 1 h and lysed in NETN buffer. Cell lysates were then subjected to immunoprecipitation using anti-PLK-1 antibody (Zymed). The PLK1 immunoprecipitates and substrate (casein) were incubated in kinase buffer (25 mM Tris-HCl (7.5 pH), 5 mM β-glycerophosphate, 2 mM dithiothreitol (DTT), 0.5 mM Na 3 VO 4 , 10 mM MgCl 2 , 0.2 mg ml -1 BSA, 10 μM ATP, 5 μCi[γ- 
